Standard versus adaptive monitoring procedures: a commentary

作者: Thomas R. Fleming

DOI: 10.1002/SIM.2641

关键词: Reliability engineeringTest statisticNull hypothesisFlexibility (engineering)Operations researchStatistical powerInterpretabilityClinical trialInterimComputer scienceClinical endpoint

摘要: In the standard approach to designing definitive clinical trials, primary endpoint and test statistic be used for analysis are specified before trial initiation. The false positive error rate null hypothesis statistical power detect targeted size of treatment effect also specified. Standard monitoring procedures, such as group sequential guidelines, enable interim while maintaining integrity this approach. contrast, adaptive procedures seek provide flexibility modify these pre-specified design features during course trial. However, have several undesirable properties, including lesser efficiency, reduced interpretability outcome results, basing changes on unreliable estimates efficacy, risks credibility trial, loss use emerging results from external sources alter key features, overemphasis importance significance relative significance.

参考文章(9)
David L. DeMets, Susan Smith Ellenberg, Thomas R. Fleming, Data Monitoring Committees in Clinical Trials: A Practical Perspective ,(2002)
Donald I Abrams, Anne I Goldman, Cynthia Launer, Joyce A Korvick, James D Neaton, Lawrence R Crane, Michael Grodesky, Steven Wakefield, Katherine Muth, Sandra Kornegay, David L Cohn, Allen Harris, Roberta Luskin-Hawk, Norman Markowitz, James H Sampson, Melanie Thompson, Lawrence Deyton, Terry Beirn Community Programs for Clinical Research on AIDS, A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection The New England Journal of Medicine. ,vol. 330, pp. 657- 662 ,(1994) , 10.1056/NEJM199403103301001
K. K. Gordon Lan, Janet Wittes, The B-value: a tool for monitoring data. Biometrics. ,vol. 44, pp. 579- 585 ,(1988) , 10.2307/2531870
Anastasios A Tsiatis, Cyrus Mehta, On the inefficiency of the adaptive design for monitoring clinical trials Biometrika. ,vol. 90, pp. 367- 378 ,(2003) , 10.1093/BIOMET/90.2.367
Christopher Jennison, Bruce W. Turnbull, Mid-course sample size modification in clinical trials based on the observed treatment effect. Statistics in Medicine. ,vol. 22, pp. 971- 993 ,(2003) , 10.1002/SIM.1457
David P. Harrington, Thomas R. Fleming, Counting Processes and Survival Analysis ,(1991)
Lu Cui, H. M. James Hung, Sue-Jane Wang, Modification of Sample Size in Group Sequential Clinical Trials Biometrics. ,vol. 55, pp. 853- 857 ,(1999) , 10.1111/J.0006-341X.1999.00853.X
S J Green, T R Fleming, J R O'Fallon, Policies for study monitoring and interim reporting of results. Journal of Clinical Oncology. ,vol. 5, pp. 1477- 1484 ,(1987) , 10.1200/JCO.1987.5.9.1477
Susan S Ellenberg, Thomas R Fleming, David L DeMets, Data Monitoring Committees in Clinical Trials : John Wiley & Sons,. ,(2002) , 10.1002/0470854162